Absolutely. We've been engaged, as has been mentioned, over the timeline. The vaccine task force did select six companies to be supported by NRC IRAP. Entos Pharmaceuticals was one of those companies. We have been working closely with some fantastic people at NRC to help us with our clinical program for bringing our vaccines to phase one clinical trials. We've received commitments of support up to $5 million to do that. Obviously, all the people working on this task are extremely dedicated, and we have gratitude for that support.
Again, and we're going to get there, we're going to get through phase one. We're talking with NRC about funding the phase two part of it. However, in the interest of speed, this needed to happen at the outset, from the very beginning, to fund the full process from beginning to end so that we could take that risk and move quicker.